"Ultimovacs is a biotechnology company focused on developing a near universal cancer peptide vaccine UV1 that targets human telomerase reverse transcriptase (known to be expressed in c 85% of cancer types). After successful completion of the Phase I programme, Ultimovacs has initiated a Phase II programme with two clinical trials running.
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase."
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase."